A Phase 1 Study of Brentuximab Vedotin in Combination With Temsirolimus in Relapsed and Refractory Hodgkin Lymphoma

Trial Profile

A Phase 1 Study of Brentuximab Vedotin in Combination With Temsirolimus in Relapsed and Refractory Hodgkin Lymphoma

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Nov 2015

At a glance

  • Drugs Temsirolimus (Primary) ; Brentuximab vedotin
  • Indications Hodgkin's disease
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 14 Dec 2014 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
    • 21 Oct 2013 Planned end date changed from 1 Dec 2014 to 1 Jun 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top